Fresh analysis reveals that individuals who come off new slimming jabs like Wegovy and Mounjaro can put back on lost weight much more quickly than those who halt traditional lifestyle plans.
Findings released in a major medical journal points out that while obese people often shed substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing such drugs must be informed of the risk of quick rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting weight in about one and a half years.
Weighing Approaches
The research, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Researchers note that people who shed pounds through diet and exercise usually have a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts propose the way of the jabs is key to understanding the accelerated regain.
These medications mimic a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication results in hunger is no longer kept in check, making overeating much more probable."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the high risk of relapse, the treatment should be considered life-long.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic nature of excess weight," similar to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication describe a intense resurgence of cravings.
"It felt as if a trigger flipping and I was suddenly ravenous," said an individual.
This difficulty is compounded if users have not developed lasting lifestyle or habit changes during treatment.
Significant Adoption
Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and long-term success relies on combined behavioural management.
